A LIFETIME OPPRTUNITY HERE GUYS ...Your opp to load up before the Investors discover this Goldmine !
This Undiscovered Gem is brutally Cheap and has Monster Upside Potential especially on the Upcoming FDA approval (1Q14) of Ablatherm-Hifu an very effective treatment for localized prostate cancer .
FDA approval + Low float = $12-15 within next Year . Please Do your own DD to realize the Full Potential in this Goldmine .GLTA
EDAP
Market Cap: $56 M
Cash: $10 M
Price: $2,50
DEBT FREE
Shares Out: 21,7 M
EDAP seeks FDA approval of its Ablatherm HIFU treatment for prostate cancer
http://www.youtube.com/watch?v=MQzaEhf7c9Y
EDAP's Ablatherm-HIFU Demonstrates Long Term Efficacy, Durability and Reproducibility With Prospective Fourteen -Year Study
Third Long Term Study Published in 2013 Validates Ablatherm-HIFU as First Line Treatment of Prostate Cancer
http://investor.edap-tms.com/release...leaseID=765946
Ablatherm? HIFU: A non-invasive treatment for prostate cancer
http://www.examiner.com/article/abla...rostate-cancer
Ablatherm-HIFU a treatment for prostate cancer is currently under regulatory review in the U.S. following submission of the Pre-Market Approval Application in February 2013 after the completion of a multi-center U.S. Phase II/III clinical trial under an Investigational Device Exemption (IDE) granted by the FDA.
Marc Oczachowski, EDAP?s chief executive officer, continued, ?Therapeutic ultrasound is gradually gaining ground in cancer treatment approach. We clearly see a growing interest in minimally invasive focal therapies for cancer tumors. Our 20 years expertise in the treatment of localized prostate cancer using HIFU has long been demonstrated and we are excited to further participate in the development of such new projects aiming at improving cancer drug delivery. While we expand our expertise in HIFU to further applications, we remain fully focused on developing our HIFU technology and adapt it to the current focal therapy trend to treat prostate cancers. We believe that the focal therapy approach represents a unique opportunity for Ablatherm HIFU to become the gold standard of treatment for prostate cancer.?